Can a single extra insulin dose speed up blood sugar control?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Diagnosis of type 2 diabetes mellitus for at least 180 days * No insulin treatment of any kind within the past 3 months * Currently treated with at least one non-insulin glucose-lowering agent (oral agent or GLP-1 receptor agonist) with inadequate glycemic control, and a clinical indication to start basal insulin * HbA1c of 7.0% to 11.0% at screening * Body mass index of 35.0 kg/m2 or lower * Able and willing to wear a continuous glucose monitor per protocol, to undergo day-4 fasting blood glucose assessment, and to attend all scheduled visits * Provides written informed consent Exclusion Criteria: * Type 1 diabetes, specific types of diabetes, or recent acute complications such as diabetic ketoacidosis or hyperosmolar hyperglycemic state * Level 2 or level 3 hypoglycemia within the past 3 months, or hypoglycemia unawareness * Current use, or use within the past 3 months, of systemic glucocorticoids (excluding inhaled or topical preparations) or other agents that markedly affect blood glucose * Moderate to severe renal impairment (eGFR below 45 mL/min/1.73 m2 by the CKD-EPI 2021 creatinine equation) or need for dialysis * Active liver disease, abnormal liver function (ALT or AST above 3 times the upper limit of normal), or decompensated cirrhosis * Marked edema, large-volume ascites, amputation, or other conditions that may impair accurate body weight measurement or distort weight-based dosing * Known allergy to insulin icodec or its excipients * Extensive skin lesions, allergy to continuous glucose monitor adhesive, or anticipated frequent magnetic resonance imaging that may interfere with monitor wear or interpretation * Active malignancy * Acute cardiovascular or cerebrovascular event (such as myocardial infarction, stroke, or unstable angina) within the past 6 months, or other major illness with short expected survival or poor compliance * Pregnancy or lactation, or women of childbearing potential with pregnancy plans * Participation in another drug or device clinical trial within the past 3 months * Other conditions judged by the investigator to be unsuitable for enrollment or likely to affect participant safety or data reliability